Jellysquid1
Posted - 16 hours ago
$CRVS Mizuho Bullshit Analysts! Oppenheimer one of the best With A RECENT $7.50 Target!
Thestocktraderhubzee
Posted - 16 hours ago
$CRVS Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
Jellysquid1
Posted - 20 hours ago
$CRVS List of institution Holders
Jellysquid1
Posted - 1 day ago
$CRVS
Jellysquid1
Posted - 2 days ago
$CRVS
Wilbean
Posted - 4 days ago
$CRVS $23 billion AD market with a huge unmet need . Miller and team will have access to rolling data out of the trial as its patient and doctor blinded, very important. The more I read about AD the more I understand Millers move into this trial. Some were disappointed that it was prioritized over the solid tumor trial, but I have no doubt a solid tumor trial will be a top priority when they have successfully addressed the cash runway . AD is a much quicker way to a partnership and a very large unmet need. So much potential, but with limited resources Miller needs to be Very strategic about where he directs them. As the entire sector dips, the fast money in crvs has moved on. IMO, not a bad thing. I also believe a partnership is imminent. Enjoy the weekend.
Orphan_Drug_Guy
Posted - 5 days ago
$CRVS been doing some DD for a while here. In after hours for a starter position. GLTA!
tradingjunk321
Posted - 5 days ago
$CRVS so true below! TRIL, FUSN, VKTX etc…. Think about it, but when others are fearful! I plan on grabbing 10k more of my Smidge bids hit! Have a great weekend!
NickeNyfiken1934
Posted - 5 days ago
@AZona $CLSD $CRVS $MREO
Jellysquid1
Posted - 5 days ago
$CRVS Thanks for the Cheap Shares!
MedicalDoctorInvestor
Posted - 5 days ago
$CRVS going sub $1 soon. Just want to point out that I was right even though many people argued with me.
Jellysquid1
Posted - 5 days ago
$CRVS Partnership Interest! Read Quote….
Berrinho91
Posted - 5 days ago
$CRVS what’s everybody’s targets on this? I guess most people are LT. how do you even define a MC for a drug where it’s TAM is north of $150B annually 😂
Berrinho91
Posted - 6 days ago
$CRVS continued to DD on this over the last week. Data so far very compelling. The potential for soquelitinib seems incredibly high. Struggling to understand why the MC is below 100M. I’m thinking it’s due to still being early in the drugs life, cash on hand and risk of dilution. If data continues to be good I guess the drug will be approved late 2026 or 2027. IMHO this is a potential multi multi bagger or BO. Feel free to add any comments, I’m really pleased I come across this and delighted to be on board for the ride 🙋♂️
Jellysquid1
Posted - 6 days ago
$CRVS NO THREAT! IV verses Oral! 👇👇👇👇👇👇
abc12332
Posted - 6 days ago
$CRVS Looks like we won’t have the only approved treatment for relapsed refractory CTCL/PTCL if 818 ultimately gets approval. T Cell lymphoma drug denileukin diftitox already approved in Japan for CTCL and PTCL. They resubmitted their BLA at the FDA’s request which the FDA accepted. A decision is expected by August but it very likely will be approved. Response rates are very similar to 818, approximately 40% with duration of response of 6 months. It requires an infusion and likely more difficult to tolerate because it’s IL2 based although they claim it was well tolerated in the trial. https://www.cancernetwork.com/view/fda-accepts-resubmitted-bla-for-denileukin-diftitox-in-r-r-ctcl
XCBatman
Posted - 6 days ago
$CRVS Did some investigation between the new 10K and the old 10Q on CRVS' changing plans for the solid tumor trial. The language went from "...for clinical investigation in a monotherapy Phase 1 clinical trial of soquelitinib in solid tumors, which we plan to initiate in the first half of 2024." to "for clinical investigation in a monotherapy trial of soquelitinib in solid tumors. We are planning a Phase 1b/2 clinical trial..." So, they added discrete information on the trial, stating that it's a Phase 1b/2 trial, but dropped it from their timeline. Coupled with the information from Conrad's data where Atopic Dermatitis supports Autoimmune (Global Sales >>$60B) vs. Solid Tumors ($13B). I wonder if this pivot directly supports a yet-to-be-announced partnership, supported by Arcara's statement on the conference call that "...our preferred partnering strategy is to find partners with development and commercialization expertise in immune disease...".
tradingjunk321
Posted - 1 week ago
$CRVS I’m on deck!
Wilbean
Posted - 1 week ago
$CRVS The herd is always predictable. Relying on others for your information instead of doing your own DD will always result in a lack of conviction in the end. I will be buying more today if it continues to dip.
Jellysquid1
Posted - 1 week ago
$CRVS Did some smidging! Could not resist at these prices!
Jellysquid1
Posted - 1 week ago
$CRVS Oppenheimer Maintains an OUTPERFORM Rating After Yesterdays Earnings Report!
XCBatman
Posted - 1 week ago
$CRVS Glad to see that my math was close!
Jellysquid1
Posted - 1 week ago
$CRVS Everybody should take 25 minutes and read for yourself what was said in yesterdays Earnings call found below on Yahoo. I am a believer in Richard Miller! Crvs will be a Winner! 👇👇👇👇👇👇👇
Thestocktraderhubzee
Posted - 1 week ago
$CRVS Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
tradingjunk321
Posted - 1 week ago
$CRVS I listened to the CC, I read the CC transcript, my thoughts are everything is on track. I think some maybe digging to deep causing some confusion. My perspective is very clear, there are things coming in the short term, and from the sound of the CC more than one partnership. Below a couple of exciting points from Miller and Arcara:
kenyonn2016
Posted - 1 week ago
$CRVS where is this 14/25 or 56% response rate for ciforadenant coming from? There’s no data in the press release and I certainly didn't hear that in the call. I would love to believe it and it would be huge news if true. But I suspect the stock would have doubled after hours if that were the case.
abc12332
Posted - 1 week ago
$CRVS Anyone who listened to the CC would appreciate your synopsis. No mention of the solid tumor Soquelitinib trial in the press release was a little concerning.
Stonksiguess
Posted - 1 week ago
$CRVS I’ll be shocked if this is not up big tomorrow. personally hoping the reaction stays muted so I can get more
tradingjunk321
Posted - 1 week ago
$CRVS